Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 3.47 USD 1.46%
Market Cap: 517.3m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Xeris Biopharma Holdings Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xeris Biopharma Holdings Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Accrued Liabilities
$67.8m
CAGR 3-Years
27%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$33.5B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$13.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$2.6B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$15.7B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$14.1B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
18%
No Stocks Found

Xeris Biopharma Holdings Inc
Glance View

Market Cap
517m USD
Industry
Pharmaceuticals

Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

XERS Intrinsic Value
3.72 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Xeris Biopharma Holdings Inc's Accrued Liabilities?
Accrued Liabilities
67.8m USD

Based on the financial report for Sep 30, 2024, Xeris Biopharma Holdings Inc's Accrued Liabilities amounts to 67.8m USD.

What is Xeris Biopharma Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
34%

Over the last year, the Accrued Liabilities growth was 20%. The average annual Accrued Liabilities growth rates for Xeris Biopharma Holdings Inc have been 27% over the past three years , 34% over the past five years .

Back to Top